Financials
Financial year 2025
CARDOEN PHARMA from Wingene, company number BE0422123016, closed financial year 2025 with a result of € 36,442 after tax. For that financial year CARDOEN PHARMA recorded a gross margin of € 95,065 and equity of € 628,114. Compared with financial year 2024, the result moved from € 125,960 to € 36,442. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 628,114
▼ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 36,442
▼ 71% vs 2024
Profit after tax over the fiscal year.
€ 45,164
▼ 71% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 53,102 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 4,472
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 25,302
▲ € 22,984 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.1 million
▲ € 895,564 vs 2024
€ 69,493 is repaid this year. At this pace the long-term loan is gone in ≈ 15 years.
€ 62,909
▲ € 61,995 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,559
▼ 98% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -9,995 | € -8,189 | € 585 | € 95,065 | ▲ € 94,480 |
| Profit after taxes | € -37,267 | € 0 | € 125,960 | € 36,442 | ▼ 71% |
| Equity | € 919,172 | € 821,448 | € 644,774 | € 628,114 | ▼ 3% |
| Total debts | € 188,673 | € 187,267 | € 465,854 | € 1,164,874 | ▲ 150% |
| Cash | € 83,868 | € 3,622 | € 155,704 | € 45,164 | ▼ 71% |
| Land & buildings | € 377,761 | € 366,551 | € 355,340 | € 979,598 | ▲ 176% |
| Retained profit | € 900,572 | € 802,848 | € 626,174 | € 609,514 | ▼ 3% |
| Dividend | € 33,901 | € 97,723 | € 302,634 | € 53,102 | ▼ 82% |
| Bank debt | € 184,756 | € 172,385 | € 159,855 | € 1,055,420 | ▲ € 895,564 |
| Balance sheet total | € 1,107,844 | € 1,008,715 | € 1,110,628 | € 1,792,988 | ▲ 61% |
Key figures of CARDOEN PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CARDOEN PHARMA?
What happened at CARDOEN PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 36,442 (▼ 71% vs 2024). Source: NBB ↗
- New establishment in Wingene. KBO
- Start of the company according to the CBE. KBO
In short
From € 37,267 loss in 2022 to € 36,442 profit in 2025.
Paid € 4,102 in corporate taxes since 2022.
Best year ever: 2024, with € 125,960 profit.
Paid out € 487,362 in dividends to the owners in total.
Management
Behind CARDOEN PHARMA is Pieter Cardoen.
Directors
According to the 2025 annual accounts
Pieter Cardoen
Director
Establishments
Establishment units
Physical locations of this company
Hoogweg 54
8750 Wingene
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0422.123.016
- VAT number
- BE 0422.123.016
- Registered office
- Hoogweg 54, 8750 Wingene
- Names & denominations
- CARDOEN PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 November 1981
- Peppol
- Active · Active since 17 Mar 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Overige zakelijke dienstverlening, neg